|
1
|
Zhu AX, Duda DG, Sahani DV and Jain RK:
HCC and angiogenesis: possible targets and future directions. Nat
Rev Clin Oncol. 8:292–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cervello M, McCubrey JA, Cusimano A,
Lampiasi N, Azzolina A and Montalto G: Targeted therapy for
hepatocellular carcinoma: novel agents on the horizon. Oncotarget.
3:236–260. 2012.PubMed/NCBI
|
|
3
|
McClune AC and Tong MJ: Chronic hepatitis
B and hepatocellular carcinoma. Clin Liver Dis. 14:461–476. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Finn RS: Emerging targeted strategies in
advanced hepatocellular carcinoma. Semin Liver Dis. 33(Suppl 1):
S11–S19. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou L, Liu J and Luo F: Serum tumor
markers for detection of hepatocellular carcinoma. World J
Gastroenterol. 12:1175–1181. 2006.PubMed/NCBI
|
|
6
|
Psyrri A, Arkadopoulos N, Vassilakopoulou
M, Smyrniotis V and Dimitriadis G: Pathways and targets in
hepatocellular carcinoma. Expert Rev Anticancer Ther. 12:1347–1357.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Viola A and Luster AD: Chemokines and
their receptors: drug targets in immunity and inflammation. Annu
Rev Pharmacol Toxicol. 48:171–197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Franciszkiewicz K, Boissonnas A, Boutet M,
Combadière C and Mami-Chouaib F: Role of chemokines and chemokine
receptors in shaping the effector phase of the antitumor immune
response. Cancer Res. 72:6325–6332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Svensson M and Agace WW: Role of
CCL25/CCR9 in immune homeostasis and disease. Expert Rev Clin
Immunol. 2:759–773. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shen X, Mailey B, Ellenhorn JD, Chu PG,
Lowy AM and Kim J: CC chemokine receptor 9 enhances proliferation
in pancreatic intraepithelial neoplasia and pancreatic cancer
cells. J Gastrointest Surg. 13:1955–1962. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johnson-Holiday C, Singh R, Johnson E, et
al: CCL25 mediates migration, invasion and matrix metalloproteinase
expression by breast cancer cells in a CCR9-dependent fashion. Int
J Oncol. 38:1279–1285. 2011.
|
|
12
|
Geisler SA, Olshan AF, Weissler MC, et al:
p16 and p53 protein expression as prognostic indicators of survival
and disease recurrence from head and neck cancer. Clin Cancer Res.
8:3445–3453. 2000.PubMed/NCBI
|
|
13
|
Fukuoka J, Fuji T, Shih JH, et al:
Chromatin remodeling factors and BRM/BRG1 expression as prognostic
indicators in non-small cell lung cancer. Clin Cancer Res.
10:4314–4324. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao Z, Zhang R, Li J, et al: X-linked
inhibitor of apoptosis protein (XIAP) regulation of cyclin D1
protein expression and cancer cell anchorage-independent growth via
its E3 ligase-mediated protein phosphatase 2A/c-Jun axis. J Biol
Chem. 288:20238–20247. 2013. View Article : Google Scholar
|
|
15
|
Ye QH, Qin LX, Forgues M, et al:
Predicting hepatitis B virus-positive metastatic hepatocellular
carcinomas using gene expression profiling and supervised machine
learning. Nat Med. 9:416–423. 2003. View
Article : Google Scholar
|
|
16
|
Yu Y, Kovacevic Z and Richardson DR:
Tuning cell cycle regulation with an iron key. Cell Cycle.
6:1982–1994. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Macaluso M, Montanari M, Cinti C and
Giordano A: Modulation of cell cycle components by epigenetic and
genetic events. Semin Oncol. 32:452–457. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakamoto N, Ebinuma H, Kanai T, et al:
CCR9+ macrophages are required for acute liver
inflammation in mouse models of hepatitis. Gastroenterology.
142:366–376. 2012.
|
|
19
|
Chu PS, Nakamoto N, Ebinuma H, et al: C-C
motif chemokine receptor 9 positive macrophages activate hepatic
stellate cells and promote liver fibrosis in mice. Hepatology.
58:337–350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amersi FF, Terando AM, Goto Y, et al:
Activation of CCR9/CCL25 in cutaneous melanoma mediates
preferential metastasis to the small intestine. Clin Cancer Res.
14:638–645. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Johnson EL, Singh R, Singh S, et al:
CCL25-CCR9 interaction modulates ovarian cancer cell migration,
metalloproteinase expression, and invasion. World J Surg Oncol.
8:622010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Singh S, Singh UP, Stiles JK, Grizzle WE
and Lillard JW Jr: Expression and functional role of CCR9 in
prostate cancer cell migration and invasion. Clin Cancer Res.
10:8743–8750. 2004. View Article : Google Scholar : PubMed/NCBI
|
